Ther Clin Risk Manag. 2006 Mar;2(1):45-57.
Nonsteroidal antiinflammatory drugs (NSAIDs), including selective cyclooxygenase (COX)-2 inhibitors, have come to play an important role in the pharmacologic management of arthritis and pain. Clinical trials have established the efficacy of etoricoxib in osteoarthritis, rheumatoid arthritis, acute gouty arthritis, ankylosing spondylitis, low back pain, acute postoperative pain, and primary dysmenorrhea. Comparative studies indicate at least similar efficacy with etoricoxib versus traditional NSAIDs. Etoricoxib was generally well tolerated in these studies with no new safety findings during long-term administration. The gastrointestinal, renovascular, and cardiovascular tolerability profiles of etoricoxib have been evaluated in large patient datasets, and further insight into the cardiovascular tolerability of etoricoxib and diclofenac will be gained from a large ongoing cardiovascular outcomes program (MEDAL). The available data suggest that etoricoxib is an efficacious alternative in the management of arthritis and pain, with the potential advantages of convenient once-daily administration and superior gastrointestinal tolerability compared with traditional NSAIDs.
非甾体抗炎药（NSAIDs），包括选择性环氧化酶（COX）-2 抑制剂，在关节炎和疼痛的药物治疗中发挥了重要作用。临床试验已经证实依托考昔在骨关节炎、类风湿关节炎、急性痛风性关节炎、强直性脊柱炎、腰痛、急性术后疼痛和原发性痛经中的疗效。对比研究表明，依托考昔与传统 NSAIDs 的疗效至少相当。在这些研究中，依托考昔总体上具有良好的耐受性，在长期给药期间没有发现新的安全性问题。依托考昔的胃肠道、肾血管和心血管耐受性已在大型患者数据集中进行了评估，并且正在进行的心血管结局研究（MEDAL）将进一步深入了解依托考昔和双氯芬酸的心血管耐受性。现有数据表明，依托考昔是关节炎和疼痛治疗的一种有效替代药物，与传统 NSAIDs 相比，具有每日一次给药方便和胃肠道耐受性更好的潜在优势。
